Effect of omalizumab on peripheral blood eosinophilia in allergic asthma

Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007 (issued January 1995, revised 2002, 2006, 2007). Available from: http://www.ginasthma.org.

Arbes, 2007, Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey, J Allergy Clin Immunol, 120, 1139, 10.1016/j.jaci.2007.07.056

Prussin, 2003, IgE, mast cells, basophils, and eosinophils, J Allergy Clin Immunol, 111, S486, 10.1067/mai.2003.120

Holgate, 2005, The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation, J Allergy Clin Immunol, 115, 459, 10.1016/j.jaci.2004.11.053

Burrows, 1989, Association of asthma with serum IgE levels and skin-test reactivity to allergens, N Engl J Med, 320, 271, 10.1056/NEJM198902023200502

Adamko, 2005, The rise of the phoenix: the expanding role of the eosinophil in health and disease, Allergy, 60, 13, 10.1111/j.1398-9995.2005.00676.x

Louis, 2000, The relationship between airways inflammation and asthma severity, Am J Respir Crit Care Med, 161, 9, 10.1164/ajrccm.161.1.9802048

Petsky, 2007, Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults (Review), Cochrane Database Syst Rev

Green, 2002, Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial, Lancet, 360, 1715, 10.1016/S0140-6736(02)11679-5

Humbert, 2005, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy, 60, 309, 10.1111/j.1398-9995.2004.00772.x

Vignola, 2004, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR), Allergy, 59, 709, 10.1111/j.1398-9995.2004.00550.x

Busse, 2001, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J Allergy Clin Immunol, 108, 184, 10.1067/mai.2001.117880

Solèr, 2001, The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, Eur Respir J, 18, 254, 10.1183/09031936.01.00092101

Holgate, 2004, Efficacy and tolerability of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma, Clin Exp Allergy, 34, 632, 10.1111/j.1365-2222.2004.1916.x

Bousquet, 2005, The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma, Allergy, 60, 302, 10.1111/j.1398-9995.2004.00770.x

Chipps, 2006, Improvement in quality of life with omalizumab in patients with severe allergic asthma, Curr Med Res Opin, 22, 2201, 10.1185/030079906X148643

Djukanović, 2004, Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma, Am J Respir Crit Care Med, 170, 583, 10.1164/rccm.200312-1651OC

MacGlashan, 1997, Down-regulation of FcɛRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody, J Immunol, 158, 1438, 10.4049/jimmunol.158.3.1438

Lin, 2004, Omalizumab rapidly decreases nasal allergic response and FɛRI on basophils, J Allergy Clin Immunol, 113, 297, 10.1016/j.jaci.2003.11.044

Beck, 2004, Omalizumab-induced reductions in mast cell FcɛRI expression and function, J Allergy Clin Immunol, 114, 527, 10.1016/j.jaci.2004.06.032

Prussin, 2003, Omalizumab treatment downregulates dendritic cell FcɛRI expression, J Allergy Clin Immunol, 112, 1147, 10.1016/j.jaci.2003.10.003

Lanier, 2003, Omalizumab is effective in the long-term control of severe allergic asthma, Ann Allergy Asthma Immunol, 91, 154, 10.1016/S1081-1206(10)62170-9

Buhl, 2002, Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma, Eur Respir J, 20, 73, 10.1183/09031936.02.00278102

Casale, 1997, Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis, J Allergy Clin Immunol, 100, 110, 10.1016/S0091-6749(97)70202-1

Stokes, 2000

Kianifard, 1995, Poisson regression analysis in clinical research, J Biopharm Stat, 5, 115, 10.1080/10543409508835101

Noga, 2003, Immunological and clinical changes in allergic asthmatics following treatment with omalizumab, Int Arch Allergy Immunol, 131, 46, 10.1159/000070434

Noga, 2006, Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma, J Allergy Clin Immunol, 117, 1493, 10.1016/j.jaci.2006.02.028

Plewako, 2002, The effect of omalizumab on nasal allergic inflammation, J Allergy Clin Immunol, 110, 68, 10.1067/mai.2002.125488

Lee, 2001, Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma, J Asthma, 38, 665, 10.1081/JAS-100107544

Wills-Karp, 1999, Immunologic basis of antigen-induced airway hyperresponsiveness, Annu Rev Immunol, 17, 255, 10.1146/annurev.immunol.17.1.255

Seminario, 1999, Intracellular expression and release of FcɛRI α by human eosinophils, J Immunol, 162, 6893, 10.4049/jimmunol.162.11.6893

Kita, 1999, Does IgE bind to and activate eosinophils from patients with allergy?, J Immunol, 1, 6901, 10.4049/jimmunol.162.11.6901

Smith, 2000, Blood eosinophils from atopic donors express messenger RNA for the alpha, beta, and gamma subunits of the high-affinity IgE receptor (Fc epsilon RI) and intracellular, but not cell surface, alpha subunit protein, J Allergy Clin Immunol, 105, 309, 10.1016/S0091-6749(00)90081-2

Kayaba, 2001, Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation, J Immunol, 167, 995, 10.4049/jimmunol.167.2.995

Pavord, 1999, Non-eosinophilic corticosteroid unresponsive asthma, Lancet, 353, 2213, 10.1016/S0140-6736(99)01813-9

van Rensen, 1999, Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma, Thorax, 54, 403, 10.1136/thx.54.5.403

Turner, 1998, Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial, Can Respir J, 5, 261, 10.1155/1998/868379

Jayaram, 2005, Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast, Thorax, 60, 100, 10.1136/thx.2004.021634

Jayaram, 2005, Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma, Eur Respir J, 25, 41, 10.1183/09031936.04.00008104